US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
LONDON (AP) — British authorities and the country’s public health service knowingly exposed tens of2024-05-21People celebrate upcoming Chinese Lunar New Year across world
(Xinhua) 13:19, February 06, 2024Students from a local school try lion dance during a cultural event2024-05-21- (People's Daily Online) 13:52, April 09, 2024Ailixier Wumaier, a 17-year-old runner from northwest C2024-05-21
London Book Fair director calls for more cultural exchange
(Xinhua) 08:38, March 14, 2024A booth displaying China-themed books is seen at London Book Fair in L2024-05-21Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-21Women of She ethnic group dress up to welcome Lunar New Year in Zhejiang
(Ecns.cn) 15:25, January 31, 2024Women of She ethnic group in traditional costumes participate in a2024-05-21
atest comment